Sanofi Halts Phase 3 Trial of Riliprubart in Rare Nerve Disease Due to Efficacy Concerns
Sanofi has stopped its Phase 3 MOBILIZE trial for riliprubart, a treatment for a rare nerve condition, after an interim review found insufficient efficacy. The decision is based on the drug's performance and not due to safety concerns.
Tickers: $SNY